ArticleCardio-oncology (London, England)2025
Validation of a novel semi-automated ECG quantification tool, applied to a cardio-oncology : Semi-automated ECG Tool applied to cardio-oncology.
Article in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundElectrocardiogram (ECG) analysis is crucial to detect cardiotoxicity. Manual methods are time-consuming and limited by inter-reader variability, highlighting the need for precise, reproducible and rapid semi-automated digital tools in clinical practice.
objectiveThis study evaluates the triplicate concatenation method (TCM) using a semi-automated ECG software (CalECG-4.2, AMPS®) by assessing intra- and inter-reader variabilities in two distinct cardio-oncology populations: breast cancer patients receiving ribociclib (a QT-prolonging drug) and patients admitted with severe immune checkpoint inhibitors (ICI)-myocarditis, a condition marked by QRS alterations.
methodsA total of 420 ECG from 31 patients (21 ribociclib, and 10 ICI-myocarditis) were independently analyzed by two readers. Variability was assessed using Bland-Altman analyses and intraclass correlation coefficients (ICC). Linear mixed-effects modelling quantified time-dependent changes in heart rate (HR), PR, QTc (Fridericia's HR correction), QRS duration and voltage (Sokolow-Lyon) accounting for inter-reader variability.
resultsIntra and inter-reader reproducibility was excellent (ICC > 0.98, including Sokolow-Lyon voltage; standard-deviation < 4 ms across all time-derived parameters). In ribociclib-treated patients (cycles of 21/28 days on drug), QTc peaked at day 14 (16 ± 1 ms, p < 0.001) before decreasing by day 28 (-6 ± 1 ms, p < 0.001) compared to baseline. In ICI-myocarditis, QRS duration increased at day 5 before returning to baseline starting day 28, while Sokolow-Lyon voltages increased progressively on immunosuppressive treatments, peaking at day 28 (458 ± 49 µV, p < 0.001) and remaining constant afterwards for the next month.
conclusionTCM with CalECG-4.2 ensures a high reproducibility while monitoring key parameters like QTc duration and Sokolow-Lyon voltage, making it a reliable and time-saving alternative for the ECG surveillance of drug toxicities in cardio-oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.